Johnson & Johnson to target eye disease treatment market through acquisition of Allyn Biosciences
JNJ Johnson & Johnson
$278.70 -1.36%
View chart & analysis → - 1Johnson & Johnson will pay an upfront payment of $2.2 billion to acquire Allyn Biosciences.
- 2Johnson & Johnson will pay an additional $1.1 billion in milestone payments, bringing the total investment in eye disease treatments to approximately $3.3 billion.
- 3Blackstone Life Sciences will provide $750 million in support for the Phase 3 clinical testing of OLN324.
So what's the key point?
What is the main point? Johnson & Johnson has decided to acquire Allyn Biosciences to enter the eye disease treatment market. The company will invest approximately $3.3 billion for this acquisition.
Source BioPharma Dive · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.